Open AccessLCZ696, Angiotensin II Receptor-Neprilysin Inhibitor, Ameliorates High-Salt-Induced Hypertension and Cardiovascular Injury More Than Valsartan Alone
Author(s) -
Hiroaki Kusaka,
Daisuke Sueta,
Nobutaka Koibuchi,
Yu Hasegawa,
Takashi Nakagawa,
Bo-Wen Lin,
Hisao Ogawa,
Shokei KimMitsuyama
Publication year - 2015
Publication title -
american journal of hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.009
H-Index - 136
eISSN - 1941-7225
pISSN - 0895-7061
DOI - 10.1093/ajh/hpv015
Subject(s) - valsartan , medicine , neprilysin , endocrinology , sacubitril , heart failure , blood pressure , renin–angiotensin system , angiotensin ii , angiotensin receptor , pharmacology , biology , enzyme , biochemistry
LCZ696, an angiotensin receptor-neprilysin inhibitor, has recently been demonstrated to exert more beneficial effects on hypertensive or heart failure patients than conventional renin-angiotensin system blockers. However, the mechanism underlying the benefit of LCZ696 remains to be understood. The present study was undertaken to examine the effect of LCZ696 compared with valsartan on hypertension and cardiovascular injury.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom